Shanghai Science and Technology Committee (STCSM), STCSM-Experimental Animal Grant, 22140903000, Construction of a new-generation Fc receptor humanized mouse model and its application in the study of intestinal cancer immunotherapy, 2022/03-2025/03

National Natural Science Foundation of China, 82030043, Elucidation of the modes of action and immunotherapeutic effector pathways of monoclonal anti-OX40 antibodies and optimization of antibody design, 2021/01-2025/12

Shanghai Science and Technology Committee (STCSM), STCSM-Preclinical studies of biological and chemical drugs, 19431902900, Preclinical study of novel agonistic antitumor CD40 antibody, 2019/04-2022/03

National Natural Science Foundation of China, 31870924, The impact and mechanism of action of IgG subclass on the pathogenicity of Dsg1-specific autoantibodies in pemphigus foliaceus, 2019/01-2022/12

National Natural Science Foundation of China, 31861143030, Targeting TIGIT-PVR interactions for cancer immunotherapy using monoclonal, 2019/01-2021/12

Ministry of Science and Technology of China, 2018ZX10302301-002, The development of diagnosis strategies and products based on specific immune responses to new M. Tuberculosis antigens, 2018/01-2021/06

Shanghai Science and Technology Committee (STCSM), STCSM-Experimental Animal Grant, 18140902600, The development and application of mice humanized for the target and Fc receptors of monoclonal antibodies, 2018/05-2021/04

Shanghai Municipal Education Commission and Shanghai Education Development Foundation, Shu Guang Scholar, 14SG16, Study of the antitumor activity and mechanism of agonistic Fc-CD40L fusion protein, 2015/01-2017/12

National Natural Science Foundation of China, National Science Fund for Excellent Young Scientists program 31422020, Targeted therapeutic molecules based on antibody Fc, 2015/01 - 2017/12

Ministry of Science and Technology of China program 2014CB943600, Post-transcriptional regulation in lymphocyte development, 2014/01 - 2018/08

National Natural Science Foundation of China, general program 31370934, The Mechanism of driving the anti-tumor activities of agonistic anti-TNFR superfamily member antibodies by inhibitory Fcgamma receptor, 2014/01 - 2017/12

Professor of Special Appointment at Shanghai Institutions of Higher Learning program，2013

National Overseas High Level Young Tanlents Program, 2013

Chen D, Zhao Y, Li M, Shang H, Li N, Li F, Wang W, Wang Y, Jin R, Liu S, Li X, Gao S, Tian Y, Li R, Li H, Zhang Y, Du M, Cao Y, Zhang Y, Li X, Huang Y, Hu LA, Li F#, Zhang H#. 2021. A general Fc engineering platform for the next generation of antibody therapeutics. Theranostics 11(4):1901-1917 (#co-corresponding) (IF = 8.579)

Zhao R, Zhang H, Zhang Y, Li D, Huang C, Li F. 2020. In Vivo Screen Identifies Zdhhc2 As a Critical Regulator of Germinal Center B Cell Differentiation. Frontiers in Immunology 11:1025 (IF=4.716)

Liu X, Zhao Y, Shi H, Zhang Y, Yin X, Liu M, Zhang H, He Y, Lu B, Jin T, Li F. 2019. Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility. Nature Communications  10(1): 4206. (IF=12.124)

Zhang W, Zhang H, Liu S, Xia F, Kang Z, Zhang Y, Liu Y, Xiao H, Chen L, Huang C, Shen N, Xu H, Li F. 2019. Excessive CD11c+Tbet+ B cells promote aberrant TFH differentiation and affinity-based germinal center selection in lupus. Proceedings of the National Academy of Sciences of the United States of America 116(37):18550-18560. (IF=9.737)

Li M, Lazorchak AS, Ouyang X, Zhang H, Liu H, Arojo OA, Yan L, Jin J, Han Y, Qu G, Fu Y, Xu X, Liu X, Zhang W, Yang Z, Ruan C, Wang Q, Liu D, Huang C, Lu L, Jiang S, Li F#, Su B#. 2019, Sin1/mTORC2 regulate B cell growth and metabolism by activating mTORC1 and Myc. Cellular & Molecular Immunology 16(9):757-769 (#co-corresponding) (IF = 7.551)

Li F#, Smith P, Ravetch JV#. 2014. Inhibitory Fcgamma Receptor Is Required for the Maintenance of Tolerance through Distinct Mechanisms. Journal of immunology 192:3021-8 (#corresponding author) (IF=5.362)

Li F#, Ravetch JV#. 2013. Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in vivo. Proceedings of the National Academy of Sciences of the United States of America 110: 19501-19506. (#corresponding author) (IF=9.737)

Li F, Ravetch JV. 2012. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcgamma receptor engagement. Proceedings of the National Academy of Sciences of the United States of America 109: 10966-10971. (IF=9.737)

Li F, Ravetch JV. 2011. Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333:1030-1034. (IF=31.201)

Li F, Yan Y, Pieretti J, Feldman DA, Eckhardt LA. 2010. Comparison of identical and functional Igh alleles reveals a nonessential role for Emu in somatic hypermutation and class-switch recombination. Journal of immunology 185:6049-6057. (IF=5.745)

Li F, Eckhardt LA. 2009. A role for the IgH intronic enhancer E mu in enforcing allelic exclusion. The Journal of experimental medicine 206:153-167. (IF=14.505)